Trial · NCT07357623
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
NCT07357623, Phase 2, Recruiting, Shanghai Chest Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors. Trials, record NCT07357623. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07357623
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
- NCT number
- NCT07357623
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 96 participants, estimated
- Lead sponsor
- Shanghai Chest Hospital
- Conditions
- Pulmonary Neuroendocrine Tumor
- Interventions
- Surufatinib Combined With Standard chemotherapy, Surufatinib
- First posted
- 2026-01-22
- Last updated
- 2026-01-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR)(RECIST1.1) | From date of enrollment to the end of treatment, an average of 1.5 years | The incidence of confirmed complete response or partial response |
| Secondary | Disease control rate (DCR)(RECIST1.1) | From date of enrollment to the end of treatment, an average of 1.5 years | Proportion of patients whose tumor volume control (reduced or enlarged) reaches a predetermined value and can maintain a minimum time limit. |
| Secondary | Progression-free Survival (PFS) (RECIST1.1) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months | A duration from the date of randomization to disease progression or death of any cause. |
| Secondary | Overall Survival (OS) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months | Duration from the date of randomization to the date of death due to any cause |
| Secondary | 4-month PFS rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months | Proportion of patients who did not develop disease progression (or death from any cause) at 4 months from the date of randomization |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07357623
GET https://conductscience.org/api/trials/v1/NCT07357623/registered